The Technical Advisory Committee (CAT) has approved this Thursday the inclusion of Laboratorios Farmacéuticos ROVI in the IBEX 35, the main stock market index in Spain. Inclusion in the IBEX is a decision taken on purely technical criteria. As of 20 December, ROVI’s share price will be included in the Spanish selective index, replacing Viscofan.
As a company, being part of the main index of the Spanish Stock Exchange is a stimulus and an incentive for all the professionals who make up ROVI to continue with the work and dedication that has already led us to be considered as one of the world’s leading companies in the pharmaceutical sector.